化学印记技术助力发现基于全反式维甲酸(ATRA)的新型低密度脂蛋白受体(LDLR)上调剂,用于治疗动脉粥样硬化
Chem-Stamp Empowered Discovery of a Novel ATRA-Based LDLR Up-Regulator for the Treatment of Atherosclerosis
Wang Shanshan, Zhang Jiarui, Wang Weiyi, Huang Dongyu, Zeng Xin, Chen Xiaoqu, Zhang Xingang, Qian Hui, Meng Linghua, Huang Linzhang, Yang Chengbin, Ma Shengming
Journal:JOURNAL OF MEDICINAL CHEMISTRY
IF:7.3
DOI:10.1021/acs.jmedchem.6c00854
PMID:42479778
Published:2026-07-21
research field:肿瘤学生物医学工程免疫学药学纳米技术癌症治疗
Abstract
Natural products and their derivatives have long served as a prolific reservoir for drug discovery. All-trans retinoic acid (ATRA) regulates lipid metabolism and shows anti-atherosclerotic potential, but its application is limited by poor drug-like properties and retinoid-related toxicity. Here, an allene-based Chem-Stamp technology has empowered the efficient construction of a diverse non-natural ATRA library by fine-tuning the number of isoprene units, the side chain, and the terminal group, leading to the identification of G301-WSS-2003 as a novel ATRA-based LDLR up-regulator. In vivo, G301-WSS-2003 , with favorable exposure and bioavailability (e.g., t 1/2 > 5 h, F > 30%), reduced serum total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) by 27%, 36%, and 26%, respectively, and significantly attenuated atherosclerotic lesion formation with no liver function abnormalities. These results highlight that Chem-Stamp is a powerful technology platform in the discovery, which results in identifying G301-WSS-2003 for further development as a promising candidate for the treatment of atherosclerosis.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


